Other indications The Australian biotech company Giaconda has developed a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine  .
Research In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine , for trials the following year .
R
Other indications The
Research In 2006 the
R
has developed a
received a European patent for a
A
, for trials the following year